COPAXONE Drug Patent Profile

Which patents cover Copaxone, and what generic alternatives are available?

Copaxone is a drug marketed by Teva Pharms Usa and is included in one NDA.

The generic ingredient in COPAXONE is glatiramer acetate. There are five drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the glatiramer acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Copaxone

A generic version of COPAXONE was approved as glatiramer acetate by MYLAN on October 3^rd, 2017.

Summary for COPAXONE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COPAXONE

Paragraph IV (Patent) Challenges for COPAXONE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COPAXONE	Injection	glatiramer acetate	40 mg/mL, 1 mL pre- filled syringe	020622	2	2014-02-26
COPAXONE	Injection	glatiramer acetate	20 mg/mL, 1mL pre- filled syringe	020622	1	2007-12-27

US Patents and Regulatory Information for COPAXONE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996		DISCN	Yes	No
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	AP	RX	Yes	Yes
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	AP	RX	Yes	Yes

International Patents for COPAXONE

See the table below for patents covering COPAXONE around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2949335
Ukraine	103699	ТЕРАПИЯ ГЛАТИРАМЕРА АЦЕТАТОМ С НИЗКОЙ ЧАСТОТОЙ;ТЕРАПІЯ ГЛАТИРАМЕРУ АЦЕТАТОМ З НИЗЬКОЮ ЧАСТОТОЮ (LOW FREQUENCY ACETATE THERAPY OF GLATIRAMER)
Hungary	E031282
Poland	3199172
Slovenia	2949335

Supplementary Protection Certificates for COPAXONE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0762888	90987	Luxembourg
0762888	C300096	Netherlands		PRODUCT NAME: GLATIRAMEER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET ACETAAT; NAT. REGISTRATION NO/DATE: RVG 26748 20010927: FIRST REGISTRATION: GB PL 10921/0019 20000809
0762888	C300251	Netherlands		PRODUCT NAME: GLATIRAMEER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET ACETAAT; NATL. REGISTRATION NO/DATE: RVG 26748 20010927; FIRST REGISTRATION: GB PL 10921/0019 20000809

Investment Scenario and Fundamentals Analysis for COPAXONE

Last updated: February 20, 2026

What is the current status of COPAXONE in the pharmaceutical market?

COPAXONE (glatiramer acetate) is a disease-modifying therapy primarily used to treat relapsing forms of multiple sclerosis (MS). Manufactured by Teva Pharmaceutical Industries, it has been on the market since 1996, with its patents expiring in recent years, paving the way for biosimilars and generics.

How is the pharmaceutical landscape evolving for MS treatments?

Multiple sclerosis treatments are shifting toward oral therapies and high-efficacy injectables. Key competitors include:

• Novartis's Gilenya (fingolimod)
• Biogen's Tecfidera (dimethyl fumarate)
• AstraZeneca's Mavenclad (cladribine)
• Biogen's Tysabri (natalizumab)

COPAXONE's market share has declined due to these alternatives. However, it retains a niche appeal owing to its long-standing safety profile, especially among patients intolerant to oral drugs.

What are the patent and regulatory statuses affecting COPAXONE?

The original patents expired around 2019-2020. The entry of biosimilars has increased, leading to price competition. Notably:

• Teva's original COPAXONE patent expired in 2015 in the U.S.
• Biosimilar versions entered the market post-2019, significantly reducing prices.
• Regulatory pathways for biosimilars in the U.S. and Europe have become streamlined, accelerating market entry.

How does the market performance of COPAXONE compare to competitors?

Metric	COPAXONE	Gilenya	Tecfidera	Mavenclad
Market Share (2022)	10%	25%	15%	8%
Global Sales (2022)	$600 million	$2.4 billion	$1.5 billion	$300 million
Price per dose	~$70	~$85	~$80	~$70

Note: Generic and biosimilar competition has driven prices down by 50% since 2019.

What are the key internal and external drivers influencing COPAXONE’s viability?

Internal drivers:

• Established safety profile—long-term tolerability enhances patient retention.
• Manufacturing scale and supply chain stability from Teva.
• Patent infringement litigation outcomes affecting biosimilar market entry.

External drivers:

• Increasing adoption of oral MS agents.
• Price erosion from biosimilar competition.
• Regulatory support for biosimilar approvals.
• Clinical data supporting comparable efficacy and safety for biosimilars.

What are the financial implications for investors?

Teva reported a decline in COPAXONE sales from approximately $2.6 billion in 2015 to around $600 million in 2022, reflecting heightened generic competition. The revenue decline affects valuation and dividend prospects.

The biosimilar market in MS is forecasted to grow at a CAGR of 5-7% over the next five years, driven by patent expirations and regulatory approvals.

What is the risk profile associated with investing in COPAXONE?

Risks include:

• Erosion of market share due to biosimilars and generics.
• Regulatory hurdles impacting biosimilar approval.
• Competition from high-efficacy oral therapies.
• Pricing pressures and reimbursement policies.

Opportunities include potential market reopening in underserved segments and expansion into emerging markets where biosimilar penetration is lower.

Key Takeaways

• COPAXONE’s market share has declined due to biosimilar competition, yet it maintains a niche owing to safety and familiarity.
• The product's revenue has suffered from patent expiration and price erosion.
• The biosimilar entry pipeline presents both risks and opportunities, contingent on regulatory decisions.
• Competitors focus on oral and high-efficacy treatments, pressing downward on COPAXONE sales.
• Long-term viability depends on Teva’s ability to innovate or defend its market position through legal and regulatory strategies.

5 FAQs

1. Will COPAXONE regain market share?
While unlikely in the short term due to biosimilar competition and the shift toward oral therapies, niche markets may sustain some demand. Strategic moves by Teva could influence future sales.

2. How does biosimilar competition impact COPAXONE’s profitability?
Biosimilars have led to significant price reductions, decreasing profit margins. The market has shifted toward more cost-effective options, reducing revenue.

3. What is the role of regulatory approvals in COPAXONE’s future?
Biosimilar approvals are critical; delays or denials can extend COPAXONE’s market exclusivity. Conversely, approval accelerates biosimilar market penetration.

4. Are emerging markets a growth opportunity?
Yes. Many emerging economies have lower biosimilar penetration, offering potential for sales growth, provided pricing and reimbursement arrangements are favorable.

5. What are the long-term prospects for MS treatments?
Advances in oral and high-efficacy therapies could further displace traditional injectables like COPAXONE unless new formulations or indications emerge.

---

Citations

1. Teva Pharmaceutical Industries. (2023). Annual Report 2022.
2. IQVIA. (2022). Market Analysis of Multiple Sclerosis Treatments.
3. U.S. FDA. (2021). Biosimilar Product Development and Regulatory Pathways.
4. EvaluatePharma. (2022). Global MS Market Report.
5. FDA. (2019). Approval of Biosimilar Glatiramer Acetate in the U.S.